Gain insights into hypothyroidism diagnosis and management and enhance your understanding of thyroid health.
Welcome to this comprehensive educational resource on hypothyroidism. My name is Dr. Alex Jimenez, and throughout this post, I will take you on a carefully structured journey through one of the most prevalent yet frequently misunderstood endocrine conditions in clinical practice. Drawing on insights from leading researchers, published clinical guidelines, and my own observations documented at PushAsRx and on my professional profile, I will walk you through the full landscape of thyroid dysfunction — from its physiological foundations to its most advanced clinical management strategies.
We will begin by exploring the fundamental physiology of the hypothalamic-pituitary-thyroid (HPT) axis, then move into the classification and root causes of hypothyroidism, including Hashimoto’s thyroiditis, iodine dysregulation, medication-induced dysfunction, post-surgical and radiation-related causes, and central hypothyroidism following traumatic brain injury. We will then discuss the diagnostic process, including laboratory testing, imaging, and antibody evaluation. From there, we will examine treatment strategies in depth — covering levothyroxine (T4), liothyronine (T3), and desiccated thyroid extract (NDT) — along with the critical principles of dosing, medication administration, and the management of special populations such as older adults and patients on amiodarone.
A significant focus of this post is on an integrative care model. I will explain how chiropractic care, functional medicine, rehabilitation, and conventional medical oversight work together to address not only thyroid hormone deficiency but also its systemic consequences. I am also honored to introduce Dr. Maria Guadalupe Cardenas, MD, who has joined our team as Medical Director and Collaborative Physician at Injury Medical Clinic PA in El Paso, Texas. Her presence elevates the level of care we can offer, and together we are committed to building a truly multidisciplinary environment that places the patient at the center of every decision.
One of the most meaningful developments in our practice has been the formalization of our multidisciplinary structure. I am proud to announce that Dr. Maria Guadalupe Cardenas, MD — Board Certified in Internal Medicine, NPI #1164426749, Texas MD License #J2933 — has joined me as Medical Director and Collaborative Physician at Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas.
Dr. Cardenas brings over 40 years of distinguished experience as an internist. Her depth of knowledge in endocrinology, cardiometabolic medicine, and complex internal medicine management provides an essential foundation for the diagnostic and therapeutic work we do for patients with thyroid disease, metabolic conditions, and related disorders. Her medical authority complements my background as a Doctor of Chiropractic, an Advanced Practice Registered Nurse (Family Nurse Practitioner), and a Certified Functional Medicine Practitioner.
This type of arrangement — an MD providing medical direction alongside a chiropractor who also holds advanced clinical credentials — is increasingly recognized as one of the most effective models in integrative and injury care settings. Here is how our team operates in practice:
This model exists because we believe that no single discipline holds all the answers to complex conditions like hypothyroidism. The synergy between medical oversight and integrative care produces outcomes that neither discipline could achieve alone.
Before we can appreciate the nuances of diagnosis and treatment, we must understand what hypothyroidism actually is and why it affects so many body systems simultaneously.
Hypothyroidism is a clinical state characterized by the reduced production and/or action of thyroid hormone, resulting in a slowing of the body’s metabolic and thermogenic processes. At its core, thyroid hormone — particularly the active form, triiodothyronine (T3) — acts on virtually every cell in the human body. It regulates basal metabolic rate, protein synthesis, lipid metabolism, cardiovascular function, neurocognitive performance, and thermogenesis (the body’s heat production). When thyroid hormone is deficient, these processes slow down in a cascading, systemic fashion.
The regulation of thyroid hormone is governed by a tightly controlled negative feedback loop involving three levels of the endocrine hierarchy:
When T3 and T4 levels are sufficient, they feed back to the hypothalamus and pituitary to suppress TRH and TSH, completing the loop. When levels fall, TRH and TSH rise in an attempt to stimulate more hormone production. This is why an elevated TSH is the hallmark laboratory finding in primary hypothyroidism — the pituitary is essentially “shouting” at a sluggish thyroid gland.
Understanding where in this axis the dysfunction originates is critical, because it determines how we interpret labs, how we treat, and what we monitor:
This classification matters enormously in clinical practice. In primary disease, TSH is a reliable and sensitive guide for treatment titration. In central disease, TSH cannot be trusted as a treatment target; instead, I monitor free T4 levels and the patient’s symptom resolution (Gharib et al., 2021).
Overt hypothyroidism affects an estimated 0.1% to 2% of the general population, though subclinical hypothyroidism — defined by elevated TSH with normal free T4 — is considerably more prevalent. The condition is significantly more common in women than in men, consistent with the broader pattern of autoimmune diseases disproportionately affecting females (Vanderpump, 2011). In my clinical experience, this epidemiological reality translates to a patient population that is predominantly female, often in their reproductive years or perimenopausal period, presenting with a constellation of symptoms that are frequently dismissed or misattributed to stress, aging, or depression.
In my clinical work, identifying the underlying driver of hypothyroidism is not merely academic — it directly shapes the treatment strategy. No two patients arrive at the same diagnosis by the same path.
In the United States, the vast majority of primary hypothyroidism is caused by Hashimoto’s thyroiditis, also called chronic autoimmune lymphocytic thyroiditis. In this condition, the immune system — for reasons that involve a complex interplay of genetic susceptibility, environmental triggers, gut permeability, and hormonal factors — mistakenly identifies thyroid tissue as foreign and mounts a sustained attack against it.
The immune response produces anti-thyroid peroxidase (anti-TPO) and antithyroglobulin (anti-TgAb) antibodies. Over time, this autoimmune inflammation causes progressive destruction of thyroid follicular cells, gradually impairing the gland’s capacity to produce T4 and T3. The gland often enlarges in a goiter during the inflammatory phase, as the body attempts to compensate, before eventually becoming atrophic in late-stage disease.
From a functional medicine perspective, identifying Hashimoto’s significantly changes the treatment conversation. Rather than simply replacing the deficient hormone, we must also address the immune dysregulation at the root of the process. This involves evaluating gut integrity (since up to 70% of the immune system is housed in the gastrointestinal tract), reducing dietary triggers of inflammation, optimizing selenium and vitamin D levels, and implementing stress management strategies that modulate the hypothalamic-pituitary-adrenal axis — all of which I integrate into our clinical plans.
On a global scale, iodine deficiency remains the most common cause of hypothyroidism, affecting populations in regions without widespread iodization programs (Vanderpump, 2011). Iodine is an irreplaceable structural component of both T4 (which contains four iodine atoms) and T3 (which contains three). Without adequate iodine, thyroid hormone synthesis cannot proceed.
In the United States, severe deficiency is rare due to salt iodization. Still, I always ask about iodine intake, particularly in patients following restrictive diets that eliminate iodized salt and seafood, or in those who have recently immigrated from iodine-deficient regions.
Paradoxically, excessive iodine can also suppress thyroid hormone synthesis through the Wolff-Chaikoff effect — a physiological mechanism by which a sudden large iodine load temporarily inhibits thyroid hormone production (Leung & Braverman, 2014). While healthy thyroid glands typically “escape” this inhibition within days, individuals with underlying autoimmune thyroiditis may not recover normally, leading to sustained hypothyroidism. I always screen patients for iodine-containing supplements (especially kelp and seaweed products) and ask about recent exposure to iodine-based radiocontrast agents used in imaging procedures.
Several commonly used medications can impair thyroid function through distinct mechanisms:
Taking a thorough medication history is non-negotiable. I have encountered patients whose thyroid dysfunction was entirely medication-driven, and in those cases, addressing the offending agent — in collaboration with the prescribing physician — is far more appropriate than simply escalating thyroid hormone replacement.
Patients who have undergone thyroidectomy (partial or total) or radioiodine ablation for hyperthyroidism or thyroid cancer will either immediately or eventually develop hypothyroidism, as functional thyroid tissue is removed or destroyed. External beam radiation to the neck or chest — as in the treatment of lymphoma, head and neck cancers, or breast cancer — can also damage the thyroid gland over time, resulting in a gradual atrophy of functional tissue. This is a cause I must always keep in mind when reviewing a patient’s oncological history, even if the radiation was administered years or decades earlier.
Not all hypothyroidism is permanent. Non-thyroidal illness syndrome (NTIS), observed in critically ill patients, involves a complex pattern of altered thyroid hormone levels — typically low T3 with variable T4 and TSH — that reflects the body’s adaptive response to severe physiological stress rather than true primary thyroid failure (Fliers et al., 2015). In these situations, I avoid rushing to initiate thyroid hormone therapy. Instead, I recheck thyroid indices 4 to 6 weeks after hospital discharge to allow the HPT axis to rebalance as the acute illness resolves.
Post-partum thyroiditis follows a similar transient pattern — an initial hyperthyroid phase followed by a hypothyroid phase — in approximately 5% to 10% of women within the first year after delivery. Most of these women ultimately recover normal thyroid function, though a subset will develop permanent hypothyroidism.
One of the areas where my combined background in chiropractic, functional medicine, and advanced clinical practice becomes particularly valuable is in recognizing central hypothyroidism secondary to traumatic brain injury (TBI). The pituitary gland is suspended from the hypothalamus by a delicate stalk and is encased in the sella turcica — a bony cavity at the base of the skull. During acceleration-deceleration injuries such as whiplash, high-impact collisions, or repeated concussions, the pituitary stalk can be sheared, bruised, or subjected to vascular compromise through microhemorrhages and edema.
The resulting post-traumatic hypopituitarism may not manifest immediately. In my clinical observations at our injury care practice, I have seen patients who appeared neurologically intact in the acute post-injury period but developed subtle endocrine changes over the following 12 to 24 months — including low or inappropriately normal TSH with low free T4, along with fatigue, cognitive impairment, exercise intolerance, and cold sensitivity (Schneider et al., 2007).
A particularly instructive case from my practice involved a law enforcement officer who sustained a high-impact crash during a vehicle pursuit. His initial post-concussive workup was largely unremarkable on standard labs. However, over the following two years, a progressive constellation of endocrine flags emerged. Pituitary MRI and comprehensive hormonal evaluation, coordinated with Dr. Cardenas, confirmed central pituitary involvement. With a carefully titrated levothyroxine regimen guided by free T4 levels — and a phased rehabilitation program addressing vestibular function, graded exertion, and neuromuscular retraining — he returned to full professional function.
This case illustrates why I routinely screen for central endocrine dysfunction in patients presenting with significant head trauma or repetitive concussive histories. It also underscores the critical rule: in suspected central hypothyroidism, evaluate adrenal sufficiency before initiating thyroid hormone therapy, as thyroid replacement can accelerate cortisol clearance and precipitate an adrenal crisis in a patient with undiagnosed adrenal insufficiency (Garber et al., 2012).
The clinical presentation of hypothyroidism is remarkably diverse, reflecting the fact that thyroid hormone affects virtually every tissue system. The degree of symptom burden depends on the duration and severity of the deficiency, as well as individual factors including age, nutritional status, and the presence of comorbidities.
The physiological basis for these symptoms lies in T3’s role in mitochondrial biogenesis and oxidative phosphorylation — the fundamental processes by which cells produce ATP (cellular energy). When T3 is deficient, mitochondrial efficiency drops, cells generate less energy, and nearly every physiological process slows. Two patients with identical TSH values can feel dramatically different depending on their peripheral T4-to-T3 conversion efficiency (governed by deiodinase activity), receptor sensitivity, iron and selenium status, and the degree of systemic inflammation (Bianco & da Conceição, 2018).
My physical examination of a patient with suspected hypothyroidism includes a meticulous, head-to-toe assessment:
While my goal is always to identify and intervene before a patient reaches advanced disease, understanding the consequences of prolonged untreated hypothyroidism informs the urgency of our diagnostic and therapeutic efforts.
One of the most clinically significant and frequently underappreciated consequences of hypothyroidism is its profound effect on lipid and cardiometabolic health. I have spent considerable time in cardiometabolic medicine, and I regularly emphasize this connection to both patients and trainees.
Thyroid hormone is a key transcriptional regulator of HMG-CoA reductase — the rate-limiting enzyme in the cholesterol biosynthesis pathway and the very target of statin medications. Thyroid hormone also upregulates hepatic LDL receptors, which are responsible for clearing LDL cholesterol from the bloodstream. When thyroid function declines, both of these mechanisms are impaired simultaneously, resulting in:
The clinical principle here — one emphasized by a cardiologist colleague of mine with over four decades of practice — is paramount: treat the thyroid first. When a patient presents with both hypothyroidism and dyslipidemia, initiating aggressive lipid-lowering therapy before restoring euthyroid status is frequently counterproductive. Once thyroid hormone levels are normalized, lipid panels often improve substantially on their own. Any residual dyslipidemia can then be addressed with confidence, knowing we are treating a primary lipid disorder rather than a secondary one. This is the root-cause principle in action (Biondi & Cooper, 2008).
In my practice, the laboratory workup for suspected hypothyroidism extends well beyond a single TSH value. A comprehensive thyroid panel, interpreted in the context of the full clinical picture, is essential for accurate diagnosis and individualized treatment.
Because hypothyroidism affects multiple organ systems, I routinely evaluate:
When evaluating thyroid function in patients recently discharged from an intensive care setting or recovering from severe systemic illness, I delay retesting for 4 to 6 weeks after hospital discharge. This allows the HPT axis to normalize as the acute inflammatory and catabolic state resolves. Premature testing in the context of non-thyroidal illness syndrome frequently yields misleading results and can lead to inappropriate initiation of thyroid hormone therapy (Fliers et al., 2015).
Thyroid ultrasound is the imaging modality of choice when structural questions arise. It is safe, non-ionizing, widely available, and highly sensitive to changes in gland architecture. I order ultrasound in the following circumstances:
In central hypothyroidism, the thyroid gland itself may appear structurally normal on ultrasound, since the failure lies upstream in the pituitary or hypothalamus. In these cases, pituitary MRI is far more informative.
Subclinical hypothyroidism — defined as a TSH between approximately 5 and 10 mIU/L with a normal free T4 — is one of the most nuanced and clinically challenging areas of thyroid medicine. Many patients in this range feel entirely well, while others present with a full constellation of hypothyroid symptoms. The laboratory definition doesn’t capture this heterogeneity, which is why I prefer to treat the patient rather than the number.
My decision-making framework incorporates the following considerations:
Patients occasionally present having researched “Wilson’s temperature syndrome” — a proposed but unvalidated clinical entity characterized by low body temperature and hypothyroid-like symptoms, purportedly treated with high-dose T3. I address this topic with transparency and scientific integrity. Current evidence does not support this as a legitimate diagnosis, and major endocrine societies, including the American Thyroid Association, advise against this label (American Thyroid Association, 2005). It is important to distinguish this from Wilson’s disease — a well-characterized genetic disorder of copper metabolism with hepatic and neurological manifestations — which is an entirely unrelated condition. When patients present with nonspecific symptoms, I rely on validated laboratory testing, a systematic differential diagnosis, and shared clinical decision-making to arrive at an accurate diagnosis.
Before discussing specific treatments, it is essential to articulate what we are actually trying to achieve. Our treatment goals in hypothyroidism are:
The mantra I return to consistently is: we treat people, not paper. If a patient’s TSH is perfectly normal but they tell me they still feel miserable, my clinical obligation is not satisfied. Conversely, if a patient’s TSH is mildly low but they feel well and have no symptoms of thyrotoxicosis, an immediate dose reduction may not serve their best interests. Clinical judgment, patient experience, and laboratory data must all be integrated.
Levothyroxine — a synthetic form of thyroxine (T4) — is the standard first-line treatment for all forms of hypothyroidism, as recommended by the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) (Garber et al., 2012). Several important pharmacological properties justify its clinical dominance:
One practical issue I emphasize to patients is the brand-versus-generic debate. The FDA permits generic medications to have a bioequivalence range of 80% to 125% of the stated dose. For most drugs, this range is clinically inconsequential. For levothyroxine — a hormone with a narrow therapeutic window — switching between different generic formulations or between brand and generic can introduce meaningful variability in TSH levels. Whenever feasible, I recommend patients stay on the same formulation consistently, whether brand-name or a single consistent generic.
Liothyronine (synthetic T3, brand names Cytomel and Triostat) is not a standard first-line therapy. Still, it is an invaluable adjunct for patients who continue to experience symptoms despite optimal levothyroxine therapy and normalized TSH. This persistent symptom burden in a subset of patients is thought to reflect impaired peripheral T4-to-T3 conversion due to polymorphisms in deiodinase genes, nutritional deficiencies, or chronic inflammation.
The pharmacological challenge with T3 is its short half-life of approximately 24 hours, which leads to more pronounced peaks and troughs in hormone levels than with T4. This often necessitates twice-daily dosing and requires careful monitoring. However, for the right patient — one whose tissue T3 levels remain suboptimal despite adequate T4 replacement — liothyronine can be genuinely life-changing (Jonklaas et al., 2014).
Desiccated thyroid extract (NDT) — derived from the dried and powdered thyroid glands of pigs (e.g., Armor Thyroid, NP Thyroid) — is the oldest form of thyroid hormone replacement, predating synthetic alternatives by many decades. It contains both T4 and T3 in a fixed ratio: one grain (approximately 65 mg) of Armor Thyroid provides roughly 38 mcg of T4 and 9 mcg of T3.
NDT is not a first-line recommendation from major endocrine societies, largely due to its fixed T4:T3 ratio and relatively high T3 content compared with human thyroid physiology. However, many patients who have not achieved satisfactory symptom resolution on levothyroxine alone report significant clinical improvement on NDT. Dosing requires patience and careful monitoring, particularly given the variable half-life resulting from the combined T4 and T3 content (Patil & Rehman, 2023). In my practice, I consider NDT on a case-by-case basis, in collaboration with Dr. Cardenas, when standard monotherapy has been optimized. Still, the patient’s quality of life remains significantly impaired.
The foundational principle of initiating thyroid hormone therapy is “go low and slow.” This is not merely a catchphrase — it reflects the physiological reality that thyroid hormone acts on every cell in the body, and that suddenly flooding tissues with supraphysiological amounts of T4 can provoke significant adverse effects, particularly in the cardiovascular and skeletal systems.
Improper medication administration is one of the most common — and most easily correctable — causes of treatment failure. I review these instructions at virtually every patient visit:
Amiodarone is a particularly complex medication in the context of thyroid management. As noted earlier, its high iodine content and structural similarity to T4 allow it to interfere with thyroid function through multiple simultaneous mechanisms: it inhibits peripheral T4-to-T3 conversion, can trigger the Wolff-Chaikoff effect, can induce destructive thyroiditis, and may also paradoxically cause hyperthyroidism (the Jod-Basedow effect). Managing thyroid function in a patient on amiodarone requires close collaboration between the internist or cardiologist managing the arrhythmia and the practitioner overseeing thyroid care (Garber et al., 2012). Thyroid function should be monitored at least every 6 to 12 months in these patients, and any decision to modify thyroid therapy must take into account the underlying cardiac condition.
Before initiating thyroid hormone therapy — particularly in patients with suspected central hypothyroidism or those with autoimmune thyroid disease — I always consider the possibility of concurrent adrenal insufficiency. Thyroid hormone replacement increases the metabolic clearance rate of cortisol; in a patient with undiagnosed Addison’s disease or adrenal insufficiency, this can precipitate a life-threatening adrenal crisis.
Schmidt’s syndrome (also known as Autoimmune Polyendocrine Syndrome Type 2, APS-2) is the co-occurrence of autoimmune thyroid disease, autoimmune adrenal insufficiency (Addison’s disease), and often Type 1 diabetes mellitus. When I encounter a patient with Hashimoto’s thyroiditis, I maintain a low threshold for screening cortisol and ACTH levels, particularly if the patient reports unexplained fatigue, hypotension, hyperpigmentation, or sodium imbalance. Treating the thyroid without first ensuring adrenal adequacy can be clinically catastrophic (Garber et al., 2012).
In patients over 65 — and especially those with underlying coronary artery disease, heart failure, atrial fibrillation, or other cardiopulmonary conditions — the “go low and slow” principle is not just a preference; it is a clinical imperative. The aging cardiovascular system is significantly more sensitive to the chronotropic and inotropic effects of excess thyroid hormone. Starting at too high a dose or escalating too quickly can precipitate tachycardia, angina, arrhythmias, or acute cardiac decompensation (Hennessey & Espaillat, 2015).
In this population, I often target a slightly higher TSH range (2.0 to 4.0 mIU/L) to provide an adequate safety margin. Close symptom monitoring and regular cardiac assessment are integrated into the follow-up plan.
Presenting complaints: Fatigue, a 4-pound weight gain, and a history of depression. Family history significant for Hashimoto’s disease.
Physical examination: Slightly enlarged thyroid gland (estimated 35 grams), dry skin.
Laboratory results:
Ultrasound: Diffusely enlarged thyroid with heterogeneous echotexture — classic for chronic autoimmune thyroiditis.
Diagnosis: Subclinical hypothyroidism secondary to Hashimoto’s thyroiditis.
Treatment decision: A full weight-based calculation suggested a target dose range of 115-129 mcg/day. This figure would have been far too aggressive for a young woman with subclinical disease and normal free hormone levels. Instead, I initiated therapy at 25 mcg of levothyroxine daily, the lowest available therapeutic dose. The rationale was to provide a gentle physiological nudge without overwhelming her system.
Six-week follow-up:
TPO antibodies, while still elevated, were not treated as a direct therapeutic target — antibody titers fluctuate and do not reliably track disease activity. The ongoing monitoring plan includes annual laboratory testing, periodic thyroid ultrasound, and earlier evaluation if symptoms recur. Sally’s case is a compelling demonstration that a small, thoughtfully chosen dose can produce a transformative clinical response.
Relevant history: Ductal carcinoma in situ (DCIS) of the breast at age 42, treated with lumpectomy and chest wall radiation (no chemotherapy). Current comorbidities: hypertension, obesity, prediabetes, total hysterectomy at age 40. Current medications: levothyroxine, telmisartan, metformin.
Laboratory and imaging findings:
Clinical approach: Jane was already on levothyroxine, so the elevated TSH signaled that her current dose of 112 mcg was no longer sufficient. Before simply raising the dose, I systematically explored the most common reasons for treatment failure:
With these factors assessed and her current dose confirmed as genuinely inadequate, I calculated her weight-based target. At 84 kg, her estimated full replacement dose was 134 to 151 mcg/day. Consistent with the “go low and slow” principle, I increased her dose from 112 mcg to the next available strength: 125 mcg daily.
Outcome: At six-week follow-up, her TSH had returned to the normal range, and she reported a meaningful improvement in energy and overall well-being. Jane’s case highlights the importance of always searching for root causes before escalating therapy, and the lasting consequences of cancer treatment on endocrine function.
Relevant history: Long-standing hypothyroidism, hypertension, cardiac arrhythmia managed with amiodarone. Currently stable on levothyroxine 125 mcg daily.
Clinical picture: John’s lab work appeared well-controlled, and his thyroid ultrasound showed no structural abnormalities. His case exemplifies the principle that stability in a complex patient requires vigilance, not complacency. Given amiodarone’s capacity to alter thyroid function through multiple mechanisms — including inhibition of T4-to-T3 conversion and iodine-mediated effects — I schedule his thyroid function testing every 6 to 12 months and conduct medication administration counseling at every visit.
The critical take-home lesson from John’s case: in patients with cardiovascular comorbidities and confounding medications, meticulous monitoring is as therapeutically important as the prescription itself.
Perhaps the most distinctive aspect of our approach at Injury Medical Clinic PA is the integration of chiropractic care, functional medicine, and rehabilitative services into the management of hypothyroidism. This is not a superficial pairing — it reflects a genuinely physiological rationale for why these disciplines contribute meaningfully to thyroid-related health outcomes.
The spine and central nervous system form the master regulatory network of the human body. The hypothalamic-pituitary-thyroid axis is ultimately a neurohormonal system — dependent on intact signaling from the central nervous system. Mechanical dysfunction in the cervical spine, including segmental restrictions, altered joint kinematics, and nociceptive drive from injured or dysfunctional cervical structures, can influence autonomic nervous system tone and thereby affect hypothalamic-pituitary signaling.
Through precise chiropractic adjustments — particularly in the upper cervical spine — I work to restore optimal joint mobility, reduce nociceptive input, and support the neurological environment in which endocrine regulation occurs. While chiropractic care does not replace thyroid hormone when true deficiency exists, it contributes to the broader physiological milieu that supports endocrine function, reduces systemic stress responses, and improves the patient’s capacity to engage in lifestyle changes that potentiate the effects of medical treatment.
Hypothyroidism impairs mitochondrial efficiency, reduces cardiovascular conditioning, and decreases muscle mass — all of which worsen fatigue, metabolic rate, and insulin sensitivity. A structured progressive rehabilitation program directly counteracts these effects.
In my rehabilitation protocols, I employ:
Resistance training, in particular, is known to upregulate mitochondrial biogenesis via PGC-1α pathways and improve insulin receptor sensitivity — both of which are directly relevant to the metabolic dysfunction that accompanies hypothyroidism. By improving the body’s cellular energy efficiency, we help patients feel better even before thyroid hormone levels have fully normalized, and we dramatically amplify the benefits of medical therapy once it is instituted.
As a Certified Functional Medicine Practitioner, I approach hypothyroidism through a systems-based lens that looks for the underlying biological imbalances driving dysfunction:
While the majority of hypothyroid patients can be effectively managed in an integrative primary care setting like ours, certain clinical scenarios warrant referral to an endocrinologist:
Before making a referral, I always revisit the fundamentals: confirm medication adherence, review administration technique, check for drug interactions, and evaluate whether a formulary or pharmacy change may have altered bioavailability.
SEO Tags: hypothyroidism, Hashimoto’s thyroiditis, subclinical hypothyroidism, overt hypothyroidism, central hypothyroidism, pituitary injury, post-concussion hypothyroidism, integrative chiropractic care, functional medicine, thyroid hormone replacement, levothyroxine dosing, liothyronine T3 therapy, desiccated thyroid extract, TSH, free T4, free T3, thyroid antibodies, anti-TPO, thyroid ultrasound, TI-RADS, selenium thyroid, iodine excess, Wolff-Chaikoff effect, dyslipidemia hypothyroidism, cholesterol thyroid, cardiometabolic health, HMG-CoA reductase, amiodarone thyroid dysfunction, adrenal insufficiency, Schmidt’s syndrome, APS-2, myxedema coma, go low and slow thyroid, rehabilitation hypothyroidism, personal injury clinic El Paso, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, El Paso Texas, multidisciplinary healthcare, evidence-based endocrinology, HPT axis, hypothalamic pituitary thyroid axis, patient-centered thyroid care
Professional Scope of Practice *
The information herein on "Diagnosis and Treatment Options for Hypothyroidism Management" is not intended to replace a one-on-one relationship with a qualified health care professional or licensed physician and is not medical advice. We encourage you to make healthcare decisions based on your research and partnership with a qualified healthcare professional.
Blog Information & Scope Discussions
Welcome to El Paso's Premier Fitness, Injury Care Clinic & Wellness Blog, where Dr. Alex Jimenez, DC, FNP-C, a Multi-State board-certified Family Practice Nurse Practitioner (FNP-BC) and Chiropractor (DC), presents insights on how our multidisciplinary team is dedicated to holistic healing and personalized care. Our practice aligns with evidence-based treatment protocols inspired by integrative medicine principles, similar to those found on this site and our family practice-based chiromed.com site, focusing on restoring health naturally for patients of all ages.
Our areas of multidisciplinary practice include Wellness & Nutrition, Chronic Pain, Personal Injury, Auto Accident Care, Work Injuries, Back Injury, Low Back Pain, Neck Pain, Migraine Headaches, Sports Injuries, Severe Sciatica, Scoliosis, Complex Herniated Discs, Fibromyalgia, Chronic Pain, Complex Injuries, Stress Management, Functional Medicine Treatments, and in-scope care protocols.
Our information scope is multidisciplinary, focusing on musculoskeletal and physical medicine, wellness, contributing etiological viscerosomatic disturbances within clinical presentations, associated somato-visceral reflex clinical dynamics, subluxation complexes, sensitive health issues, and functional medicine articles, topics, and discussions.
We provide and present clinical collaboration with specialists from various disciplines. Each specialist is governed by their professional scope of practice and their jurisdiction of licensure. We use functional health & wellness protocols to treat and support care for musculoskeletal injuries or disorders.
Our videos, posts, topics, and insights address clinical matters and issues that are directly or indirectly related to our clinical scope of practice.
Our office has made a reasonable effort to provide supportive citations and has identified relevant research studies that support our posts. We provide copies of supporting research studies upon request to regulatory boards and the public.
We understand that we cover matters that require an additional explanation of how they may assist in a particular care plan or treatment protocol; therefore, to discuss the subject matter above further, please feel free to ask Dr. Alex Jimenez, DC, APRN, FNP-BC, or contact us at 915-850-0900.
We are here to help you and your family.
Blessings
Dr. Alex Jimenez DC, MSACP, APRN, FNP-BC*, CCST, IFMCP, CFMP, ATN
email: coach@elpasofunctionalmedicine.com
Multidisciplinary Licensing & Board Certifications:
Licensed as a Doctor of Chiropractic (DC) in Texas & New Mexico*
Texas DC License #: TX5807, Verified: TX5807
New Mexico DC License #: NM-DC2182, Verified: NM-DC2182
Multi-State Advanced Practice Registered Nurse (APRN*) in Texas & Multi-States
Multistate Compact APRN License by Endorsement (42 States)
Texas APRN License #: 1191402, Verified: 1191402 *
Florida APRN License #: 11043890, Verified: APRN11043890 *
Verify Link: Nursys License Verifier
* Prescriptive Authority Authorized
ANCC FNP-BC: Board Certified Nurse Practitioner*
Compact Status: Multi-State License: Authorized to Practice in 40 States*
Graduate with Honors: ICHS: MSN-FNP (Family Nurse Practitioner Program)
Degree Granted. Master's in Family Practice MSN Diploma (Cum Laude)
Dr. Alex Jimenez, DC, APRN, FNP-BC*, CFMP, IFMCP, ATN, CCST
(Board Certified: Family Practice Nurse Practitioner—Multistate)*
(Licensed Nurse Practitioner & Chiropractor - Multistate)*
Clinical Director
Digital Business Card
Dr. Maria Cardenas, MD
(Board Certified: Internal Medicine)
(Licensed Medical Doctor)
Medical Director, Clinical Director & Collaborative Physician
NPI # 1164426749
MD License #: J2933
Licenses and Board Certifications:
MD: Medical Doctor
DC: Doctor of Chiropractic
APRNP: Advanced Practice Registered Nurse
FNP-BC: Family Practice Specialization (Multi-State Board Certified)
RN: Registered Nurse (Multi-State Compact License)
CFMP: Certified Functional Medicine Provider
MSN-FNP: Master of Science in Family Practice Medicine
MSACP: Master of Science in Advanced Clinical Practice
IFMCP: Institute of Functional Medicine
CCST: Certified Chiropractic Spinal Trauma
ATN: Advanced Translational Neutrogenomics
Memberships & Associations:
TCA: Texas Chiropractic Association: Member ID: 104311
AANP: American Association of Nurse Practitioners: Member ID: 2198960
ANA: American Nurse Association: Member ID: 06458222 (District TX01)
TNA: Texas Nurse Association: Member ID: 06458222
NPI: 1205907805
| Primary Taxonomy | Selected Taxonomy | State | License Number |
|---|---|---|---|
| No | 111N00000X - Chiropractor | NM | DC2182 |
| Yes | 111N00000X - Chiropractor | TX | DC5807 |
| Yes | 363LF0000X - Nurse Practitioner - Family | TX | 1191402 |
| Yes | 363LF0000X - Nurse Practitioner - Family | FL | 11043890 |
| Yes | 363LF0000X - Nurse Practitioner - Family | CO | C-APN.0105610-C-NP |
| Yes | 363LF0000X - Nurse Practitioner - Family | NY | N25929 |
Dr. Alex Jimenez, DC, APRN, FNP-BC*, CFMP, IFMCP, ATN, CCST
(Board Certified: Family Practice Nurse Practitioner—Multistate)*
(Licensed Nurse Practitioner & Chiropractor - Multistate)*
Clinical Director
Digital Business Card
Dr. Maria Cardenas, MD
(Board Certified: Internal Medicine)*
(Licensed Medical Doctor)*
Medical Director, Clinical Director & Collaborative Physician
NPI # 1164426749
MD License #: J2933
Why Attorneys Refer MVA Patients to Integrative Care After a car crash, many people feel… Read More
Sports Injury Recovery With Orthopedic Chiropractic: A Functional Unit Approach to Lasting Recovery Abstract In… Read More
By Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST Read More
By Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST Read More
Slip and Fall Accidents: Injury Recovery Guide Have you ever slipped on a wet floor… Read More
by: Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST Read More
Personal Injury, Trauma & Spine Rehab Specialists